BIT Capital’s Arcus Biosciences RCUS Stock Holding History

BIT Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,000	Closed	-$134K	–	133
2023 Q4	$134K	Buy	+7,000	New	+$112K	0.01%	82

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BIT Capital's RCUS Position: Q1 2024 in Review

BIT Capital sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 7,000 shares — an estimated $134K sold.

BIT Capital first reported a position in RCUS in Q4 2023 and held it in 1 quarter. The position peaked at $134K in Q4 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

BIT Capital reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
BIT Capital sold 7,000 Arcus Biosciences shares in Q1 2024, an estimated $134K.
BIT Capital first reported a position in Arcus Biosciences in Q4 2023 and held it in 1 quarter.
BIT Capital's Arcus Biosciences position peaked at $134K in Q4 2023.
172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on BIT Capital's 13F filing for Q1 2024, filed 12 Feb 2025.